Therapy News and Research

RSS

ESWT applied with SANUWAVE’s Ossatron device results in 80% healing rate of nonunions of the tibia

SANUWAVE Health, Inc.,, an emerging medical technology company focused on the development and commercialization of non-invasive, biological response activating devices in the regenerative medicine area, today announced that a journal article titled Extracorporeal Shock Wave Therapy for Nonunion of the Tibia, was published in the March 2010 issue of the Journal of Orthopedic Trauma.

10 Mar 2010

Astra Tech's OsseoSpeed TX implant line launched to the US market at AO Annual Meeting

Astra Tech, leading provider of comprehensive solutions for dental implant therapy, launched their OsseoSpeed™ TX implant line to the US market at this year’s AO Annual Meeting. The OsseoSpeed™ TX implant comes as the next step in the continuous evolution of the Astra Tech Implant System™ with its modified tapered apex design, first introduced with the launch of their narrow two-piece implant, OsseoSpeed™ TX 3.0 S in June 2008.

10 Mar 2010

Idera Pharmaceuticals announces net income of $3.9M for fourth-quarter 2009

Idera Pharmaceuticals, Inc. today reported financial results for the fourth quarter and full year ended December 31, 2009.

10 Mar 2010

Few CE studies compare medications with nonpharmacologic interventions, and examine safety or cost-effectiveness

An analysis of comparative effectiveness studies finds that few compare medications with nonpharmacologic interventions, and few examine safety or cost-effectiveness, according to a study in the March 10 issue of JAMA.

10 Mar 2010

Springer to publish Nuclear Medicine and Molecular Imaging

NMMI publishes original research papers, reviews, case reports, editorials and letters to the editor on nuclear medicine and a wide range of related sciences. These include radiochemistry, radiopharmacy, dosimetry and pharmacokinetics/pharmacodynamics of radiopharmaceuticals, nuclear and molecular imaging analysis, nuclear and molecular imaging instrumentation, radiation biology and radionuclide therapy. June-Key Chung, MD, PhD, from the Seoul National University College of Medicine will serve as editor-in-chief. He will be supported by an international editorial board.

10 Mar 2010

Children's Hospital Boston develops new web site, releases video message on current state of stem cell research

Exactly one year to the day after President Obama's historic decision to reverse an eight-year restriction on federally funded embryonic stem cell research, the Children's Hospital Boston Stem Cell Program today announced the development of a unique, comprehensive web site and released a candid video message from its top researchers on the current state of stem cell research to introduce the new site: stemcell.childrenshospital.org.

10 Mar 2010

BIOCRATES Life Sciences, CHENOMX announce co-marketing agreement

Austrian biomarker developer BIOCRATES Life Sciences AG announced today that it entered a co-marketing agreement with Canadian-based CHENOMX Inc. Both enterprises focus on a new and highly promising technology aimed at generating a metabolic profile of the human organism that can be used to monitor the effects of disease, nutrition, toxins, environment, or drugs on an organism.

10 Mar 2010

Two core premises underlie MSI's mission to broaden access to surgical choice and quality

Two core premises underlie Mobile Surgery International's mission to broaden access to surgical choice and quality. The first is that patients (and payers) should be able to make decisions about surgical options based upon access to complete information up front about all of the necessary services associated with their surgical procedure, the skill and expertise of the surgeon carrying out the procedure, and the total costs involved.

10 Mar 2010

Japanese ablation devices market: Emerging trends that will fuel market growth

According to Millennium Research Group, the global authority on medical technology market intelligence, the recent launch of irrigated-tip catheters into the Japanese market will drive the ablation catheter market by a compound annual growth rate of approximately 15% through 2014.

10 Mar 2010

Imaging tools may help address challenging clinical dilemma of prostate cancer care: Study

New preliminary data from a pilot study in the Netherlands indicates that imaging tools may help address the most challenging clinical dilemma of prostate cancer care as identified by the hearing of the House Oversight and Government Reform Committee and its expert witnesses last week: to treat or not treat, AdMeTech Foundation's President and CEO Dr. Faina Shtern said today.

10 Mar 2010

Papaya's anticancer effect against broad range of lab-grown tumors documented

The humble papaya is gaining credibility in Western medicine for anticancer powers that folk cultures have recognized for generations.

10 Mar 2010

Augmentation with ketone bodies improves cognitive function in AD patients

Accera, Inc., a biotechnology company delivering breakthrough therapies in central nervous system diseases, announced data which showed that augmentation with ketone bodies significantly improved cognitive function in Alzheimer's disease (AD) patients.

10 Mar 2010

AMT initiates dosing in Phase I/II gene therapy clinical trial for hemophilia B

Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, announced today that the first patient has been dosed in the Phase I/II exploratory clinical trial with a gene therapy product for hemophilia B, a seriously debilitating and potentially lethal disease.

10 Mar 2010

Bristol-Myers Squibb, AstraZeneca commence SAVOR-TIMI 53 trial of ONGLYZA for type 2 diabetes

Bristol-Myers Squibb Company and AstraZeneca today announced the commencement of the “Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus” trial, a multicenter, randomized, double-blind, placebo-controlled Phase 4 study, to evaluate treatment with ONGLYZA™ (saxagliptin), a dipeptidyl peptidase-4 inhibitor, in adult type 2 diabetes patients with cardiovascular risk factors.

10 Mar 2010

SPO Medical signs MOU with MetroSleep

SPO Medical Inc., a leading developer of biosensor and microprocessor technologies for use in portable monitoring devices, today announced it has signed a Memorandum of Understanding (MOU) with MetroSleep Inc, a US corporation that specializes in products to diagnose and treat sleep apnea through at-home testing. The MOU enables the integration of SPO Medical' ASIC chip-set technology in a new MetroSleep product offering for the Sleep Disturbance Breathing monitoring market.

10 Mar 2010

Skin transplant surgery safe and effective for treating vitiligo

In the first study of its kind in the United States, Henry Ford Hospital showed that skin transplant surgery is safe and effective for treating vitiligo.

10 Mar 2010

Cellectar completes enrollment in (131)I-CLR1404 Phase I dosimetry trial for advanced solid malignancies

Cellectar, Inc., a privately held radiopharmaceutical company that designs and develops products to detect, treat and monitor human cancers, today announced that enrollment for its Phase I dosimetry trial for its lead drug candidate, (131)I-CLR1404 has been completed. Results of this trial will be used to set the starting dose in a follow-on Phase I dose escalation study planned for later this year. Institutions that participated in the trial include City of Hope, Duke University Medical Center, Georgetown University/Lombardi Cancer Center, and Johns Hopkins Hospital.

10 Mar 2010

Side-Out Foundation sponsors new advanced breast cancer clinical trial

The Side-Out Foundation, which pairs volleyball enthusiasts with breast cancer researchers, is sponsoring a new clinical trial for up to 25 patients with advanced breast cancer.

10 Mar 2010

Obesity linked to increased risk of cancer recurrence and death

It’s long been known that obesity is linked to increased risk of developing colon cancer, but now researchers at the Mayo Clinic campus in Minnesota have found that obesity is associated with worse outcomes in patients who have already been diagnosed and treated for the cancer.

10 Mar 2010

Spasticity in flexor muscles of elbow, wrist, and fingers: Botox approved for treatment

The U.S. Food and Drug Administration today approved Botox (onabotulinumtoxin A) to treat spasticity in the flexor muscles of the elbow, wrist, and fingers in adults. Spasticity is common after stroke, traumatic brain injury, or the progression of multiple sclerosis.

10 Mar 2010

Therapy News and Research

ESWT applied with SANUWAVE’s Ossatron device results in 80% healing rate of nonunions of the tibia

Astra Tech's OsseoSpeed TX implant line launched to the US market at AO Annual Meeting

Idera Pharmaceuticals announces net income of $3.9M for fourth-quarter 2009

Few CE studies compare medications with nonpharmacologic interventions, and examine safety or cost-effectiveness

Springer to publish Nuclear Medicine and Molecular Imaging

Children's Hospital Boston develops new web site, releases video message on current state of stem cell research

BIOCRATES Life Sciences, CHENOMX announce co-marketing agreement

Two core premises underlie MSI's mission to broaden access to surgical choice and quality

Japanese ablation devices market: Emerging trends that will fuel market growth

Imaging tools may help address challenging clinical dilemma of prostate cancer care: Study

Papaya's anticancer effect against broad range of lab-grown tumors documented

Augmentation with ketone bodies improves cognitive function in AD patients

AMT initiates dosing in Phase I/II gene therapy clinical trial for hemophilia B

Bristol-Myers Squibb, AstraZeneca commence SAVOR-TIMI 53 trial of ONGLYZA for type 2 diabetes

SPO Medical signs MOU with MetroSleep

Skin transplant surgery safe and effective for treating vitiligo

Cellectar completes enrollment in (131)I-CLR1404 Phase I dosimetry trial for advanced solid malignancies

Side-Out Foundation sponsors new advanced breast cancer clinical trial

Obesity linked to increased risk of cancer recurrence and death

Spasticity in flexor muscles of elbow, wrist, and fingers: Botox approved for treatment

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News